CG Invites Co., Ltd.

Biopharma advancing precision medicine with drugs, mRNA vaccines, and digital therapeutics.

083790 | KO

Overview

Corporate Details

ISIN(s):: N/A
LEI:
Country:: South Korea
Address:: 서울특별시 강서구 마곡중앙8로 38 마곡동, 강서구
Website:: https://cginvites.com/en
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CG Invites Co., Ltd. is a biopharmaceutical company specializing in digital genomics and personalized precision medicine. Leveraging its core competency in developing novel chemical and biological drugs—such as Acelex (osteoarthritis), Ivaltinostat (pancreatic cancer), and Camrelizumab (immuno-oncology)—the company has expanded its focus to several key areas. These include whole genome sequencing, contributing to large-scale bio-data projects; the development of personalized, mRNA-based cancer vaccines targeting tumor-specific neoantigens; and digital therapeutics (DTx), exemplified by its HealthOnG platform for diabetes management. The company's strategy is to innovate within the digital genome market by integrating its drug development expertise with cutting-edge genomic and digital health technologies.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for CG Invites Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Date	Filing	Language	Size	Actions
2025-08-14 00:00	Interim Report 반기보고서 (2025.06)	Korean	1.8 MB
2025-08-14 00:00	Major Shareholding Notification 임원ㆍ주요주주특정증권등소유상황보고서	Korean	34.7 KB

Automate Your Workflow. Get a real-time feed of all CG Invites Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for CG Invites Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
SoftOx Solutions AS Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.	Norway	SOFTX
Solasia Pharma K.K. In-licenses and commercializes oncology treatments and supportive care products in Asia.	Japan	4597
Sopharma AD Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.	Bulgaria	SFA
Spago Nanomedical AB Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.	Sweden	SPAGO
Spexis AG Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.	Switzerland	SPEX
Sprint Bioscience Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.	Sweden	SPRINT
STADA Arzneimittel AG A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.	Germany	SAZ
Stayble Therapeutics AB Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.	Sweden	STABL
STCUBE Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.	South Korea	052020
STELLA PHARMA CORPORATION Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.	Japan	4888